{"id":49227,"date":"2022-10-06T00:01:51","date_gmt":"2022-10-05T22:01:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/"},"modified":"2022-10-06T00:01:51","modified_gmt":"2022-10-05T22:01:51","slug":"harrow-sells-non-ophthalmic-compounding-business","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/","title":{"rendered":"Harrow Sells Non-Ophthalmic Compounding Business"},"content":{"rendered":"
\n

NASHVILLE, Tenn.–(BUSINESS WIRE)–$HROW<\/a>–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non\u2011ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (\u201cRevelation\u201d).\n<\/p>\n

<\/a><\/p>\n

\nPursuant to the terms of the transaction, Revelation purchased the assets of Harrow\u2019s non\u2011ophthalmic compounding business, including its formulations, customer accounts, and other related assets. The transaction did not involve a pharmaceutical production or dispensing facility. Harrow will continue to support Revelation during an estimated three-month transition period, and Revelation will offer employment to Harrow employees supporting the acquired business.\n<\/p>\n

\n\u201cThis transaction is consistent with Harrow\u2019s strategic vision to focus exclusively on ophthalmic medicines \u2013 to be a \u2018pure play\u2019 ophthalmic pharmaceuticals company<\/i>,\u201d said Mark L. Baum, Harrow\u2019s Chairman and Chief Executive Officer. \u201cAs we approach several key milestones, including the upcoming commercial launch of recently FDA-approved IHEEZO<\/a>\u2122; the launch of our patent\u2011pending Fortisite<\/a>\u2122 compounded combination antibiotics; the outcome of the MELT\u2011300<\/a> pivotal efficacy study, expected before the end of this year, for one of our former subsidiaries, Melt Pharmaceuticals<\/a>; progress on product acquisition activities we are pursuing, and new ophthalmic compounded product launches expected in the coming months, we believe this transaction demonstrates our resolve to concentrate on our core competencies and commercial expertise in the North American ophthalmic pharmaceuticals market. Going forward, our capital allocation strategy, including proceeds from this transaction, will be aimed at expanding Harrow\u2019s branded ophthalmic product portfolio.\u201d\n<\/p>\n

\nAbout Harrow<\/b>\n<\/p>\n

\nHarrow (Nasdaq: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable. For more information about Harrow, including investor-related materials, please visit the corporate website, harrowinc.com<\/a>, or Harrow\u2019s LinkedIn<\/a> page.\n<\/p>\n

\nAbout Revelation Pharma Corporation<\/b>\n<\/p>\n

\nRevelation Pharma is a national network of 503A and 503B compounding pharmacies providing innovative and quality pharmaceutical products and services through \u201cindustry best\u201d patient care and solutions for customers. Revelation Pharma<\/a> is owned by Osceola Capital<\/a>, a Tampa-based private equity firm that invests in lower middle-market services companies.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:
\n
Jamie Webb
\n
Director of Communications and Investor Relations
\n
jwebb@harrowinc.com<\/a><\/span>
615-733-4737\n<\/p>\n

\nMedia:
\n
Deb Holliday
\n
Holliday Communications, Inc.
\n
deb@hollidaycommunications.net<\/a><\/span>
412-877-4519\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NASHVILLE, Tenn.–(BUSINESS WIRE)–$HROW–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non\u2011ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (\u201cRevelation\u201d). Pursuant to the terms of the transaction, Revelation purchased the assets of Harrow\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49227","6":"format-standard","7":"category-industry"},"yoast_head":"\nHarrow Sells Non-Ophthalmic Compounding Business - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harrow Sells Non-Ophthalmic Compounding Business - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NASHVILLE, Tenn.–(BUSINESS WIRE)–$HROW–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non\u2011ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (\u201cRevelation\u201d). Pursuant to the terms of the transaction, Revelation purchased the assets of Harrow\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T22:01:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221005005735\/en\/1593274\/21\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Harrow Sells Non-Ophthalmic Compounding Business\",\"datePublished\":\"2022-10-05T22:01:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/\"},\"wordCount\":385,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005735\\\/en\\\/1593274\\\/21\\\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/\",\"name\":\"Harrow Sells Non-Ophthalmic Compounding Business - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005735\\\/en\\\/1593274\\\/21\\\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg\",\"datePublished\":\"2022-10-05T22:01:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005735\\\/en\\\/1593274\\\/21\\\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005735\\\/en\\\/1593274\\\/21\\\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harrow-sells-non-ophthalmic-compounding-business\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harrow Sells Non-Ophthalmic Compounding Business\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harrow Sells Non-Ophthalmic Compounding Business - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/","og_locale":"en_US","og_type":"article","og_title":"Harrow Sells Non-Ophthalmic Compounding Business - Pharma Trend","og_description":"NASHVILLE, Tenn.–(BUSINESS WIRE)–$HROW–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non\u2011ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (\u201cRevelation\u201d). Pursuant to the terms of the transaction, Revelation purchased the assets of Harrow\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-05T22:01:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221005005735\/en\/1593274\/21\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Harrow Sells Non-Ophthalmic Compounding Business","datePublished":"2022-10-05T22:01:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/"},"wordCount":385,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005735\/en\/1593274\/21\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/","url":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/","name":"Harrow Sells Non-Ophthalmic Compounding Business - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005735\/en\/1593274\/21\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg","datePublished":"2022-10-05T22:01:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221005005735\/en\/1593274\/21\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221005005735\/en\/1593274\/21\/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/harrow-sells-non-ophthalmic-compounding-business\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Harrow Sells Non-Ophthalmic Compounding Business"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49227"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49227\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}